Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05528952 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Study acronym: TERTIO
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv8
  2. Primary completion date: Apr 27, 2025 to Mar 27, 2028
    • Study sites: 12 to 14
    • Study completion date: Sep 27, 2029 to Feb 27, 2030
    • Publications: details revised at 1 of 1 entry
    v7
  3. Primary completion date: Apr 30, 2025 to Apr 27, 2025
    • Study completion date: Sep 30, 2027 to Sep 27, 2029
    • Eligibility criteria shortened, about 1 word
    v6
  4. Study sites: 10 to 12v5
  5. Study sites: 11 to 10v4
Show 2 earlier versionsHide 2 earlier versions
  1. Collaborators: 1 to 2v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 11
    • Start date changed from estimate of Sep 30, 2022 to Sep 27, 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)
Trial Details
NCT Number NCT05528952
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Collaborators: GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov